证券代码：300255 证券简称：常山药业 编号：2014-2 河北常山生化药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------|----------------------------------------|------------------------------------|----------------------------------------------------|--------| | | √ 特定对象调研 | □ 分析师会议 | | | | 投资者关系活动 | □ 媒体采访 □ | 业绩说明会 | | | | 类别 | □ 新闻发布会 | □ 路演活动 | | | | | □ 现场参观 | | | | | | □ 其他 | （请文字说明其他活动内容） | | | | | 天安财产保险 | 党新星 | 北京大君智萌 | 李红 | | 参与单位名称及 | 北京大君智萌 | 庄伟 | 北京大君智萌 | 杨永清 | | 人员姓名 | 民生证券 | 张金洋 | 深圳裕晋投资 | 许杰 | | ...

Group 1: Company Overview - Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is involved in the production of heparin and related products [2] - The company has received registration approval for its new product, Dahuansuan, and has passed the new GMP certification [2] Group 2: Product Development and Market Strategy - The company is actively developing new products, including low molecular weight heparin and Eptifibatide, which are currently awaiting approval [2] - The market for hyaluronic acid appears promising, although current production levels are low [3] Group 3: Supply Chain and Production - The company primarily sources heparin raw materials domestically, with foreign procurement being a minor part [3] - The production workshop for formulations is built according to FDA standards [3] Group 4: Market Coverage and Sales - The low molecular weight heparin injection has approximately 50% coverage in top-tier hospitals, with nearly 2,000 hospitals nationwide using the product [3] - The company’s Dahuansuan raw material is mainly for internal use, while the Jiangsu subsidiary sells its heparin sodium raw materials externally [3]

证券代码：300255 证券简称：常山药业 编号：2014-5 河北常山生化药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |----------------|----------------|--------------------|----------------------------------------|----------------------------------------------------| | | √ 特定对象调研 | □ | 分析师会议 | | | 投资者关系活动 | □ 媒体采访 | □ | 业绩说明会 | | | 类别 | □ 新闻发布会 | □ | 路演活动 | | | | □ 现场参观 | | | | | | □ 其他 | | （请文字说明其他活动内容） | | | | 国泰君安 | 王超伟 | 长安基金 | 杨小馨 | | 参与单位名称及 | 千石创富 | 陈仕飞 | 民生证券 | 张金洋 | | 人员姓名 | 兴业证券 | 徐佳熹 | 中航证券 | 胡厚中等 | | 时间 | 2014 年 11 | 月 6 ...

证券代码：300255 证券简称：常山药业 河北常山生化药业股份有限公司 投资者关系活动记录表 编号：2015-1 | --- | --- | --- | |----------------|--------------------------------|------------------------------------------------------------| | | √ 特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 □ | 业绩说明会 | | 类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 宏道投资 杨洁 | 全尔晖 | | 人员姓名 | 天安财险 党新星 | | | | | | | 时间 | 2015 年 10 月 29 日 | 上午 9:45 | | 地点 | | 河北常山生化药业股份有限公司会议室 | | 上市公司接待人 | 董事会秘书 : 张威 | | | 员姓名 | | | | | | 一、董秘张威介绍了公司三季度经营情况 | | | 二、就公 ...

Group 1: Company Overview and Market Position - The price of heparin sodium raw materials is currently at a relatively low point, with limited downward space [2] - The new low molecular weight heparin raw material workshop has passed German GMP and US FDA certification, which is expected to become a growth point for the company [2] - Sales of low molecular weight heparin calcium injection have been steadily increasing in recent years, and the company's first generic drug, heparin sodium injection, has entered the market and is expected to achieve rapid growth [2] Group 2: Future Plans and Collaborations - The company plans to export heparin preparations to Europe and the US, having already partnered with D.Med Healthcare GmbH&Co.KG in Germany to establish a joint venture for secondary packaging to sell in the European market [2] - The first blood dialysis center is being standardized and has been completed, awaiting expert group acceptance [3] - Clinical trials for Abiraterone have entered Phase I [3] Group 3: Product Development and Regulatory Status - The supplementary application for sildenafil raw materials and formulations was submitted to the National Medical Products Administration in the first half of 2015 and has been accepted; the corresponding production workshop is completed and awaits drug registration approval and GMP certification [3] - The bidding results for low molecular weight heparin calcium injection this year have been good, with stable winning prices; the heparin sodium injection is in the gradual development stage due to its new market entry [3] - The company is currently producing cosmetic-grade and food-grade hyaluronic acid in its pilot workshop, with a new production workshop under construction [3]

证券代码：300255 证券简称：常山药业 编号：2016-2 河北常山生化药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------|-------------------------------------|----------------------------------------------------|------------------| | | √ 特定对象调研 □ | 分析师会议 | | | 投资者关系活动 | □ 媒体采访 □ | 业绩说明会 | | | 类别 | □ 新闻发布会 □ | 路演活动 | | | | □ 现场参观 | | | | | □ 其他 （请文字说明其他活动内容） | | | | | 兴业证券 徐佳熹 | 工银瑞信基金 | 谭冬寒 | | 参与单位名称及 | 平安资产 黄文峰 | 中再资产 | 常翟子 | | 人员姓名 | 上海博颐投资 马善尧等 | | | | 时间 | 2016 年 6 月 20 日 上午 | 10:00 | | | 地点 | 河北常山生化药业股份有限公司会议室 | | | | 上 ...

Group 1: Company Overview and Operations - Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is focused on the development of hyaluronic acid and heparin series products [1] - The company is currently preparing to apply for production of injectable hyaluronic acid to the National Medical Products Administration [1] - The new hyaluronic acid workshop is designed with a production capacity of 20 tons, while the current capacity for food-grade and cosmetic-grade hyaluronic acid is approximately 1,000 kg [2] Group 2: Product Development and Clinical Trials - The company is collaborating with American Huangxinxiang to develop a new diabetes treatment, Aibennate, which is currently in Phase I clinical trials and progressing well [2] - The company plans to produce pharmaceutical-grade, food-grade, and cosmetic-grade products in the new hyaluronic acid workshop [2] Group 3: Market Strategy and Future Plans - The company is exploring acquisition opportunities in the pharmaceutical, medical services, and medical device sectors to support strategic growth [3] - The company aims to establish a blood dialysis center to meet the demand in Shijiazhuang and surrounding areas, addressing the current shortfall in public hospital capacity [3] - The independent dialysis center will focus on providing superior service and hygiene compared to public hospitals, leveraging collaboration with German D-Med for advanced dialysis standards [3]

证券代码：300255 证券简称：常山药业 编号：2016-3 河北常山生化药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |------------------------------------|--------------------------------|-----------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | √ 特定对象调研 | □ 分析师会议 | | | 投资者关系活动 | □ 媒体采访 | □ 业绩说明 ...